Last week saw three studies with seemingly contradictory results about the antiviral drug remdesivir, culminating in the Food and Drug Administration (FDA) granting Emergency Use Authorization (EUA).
What happened, exactly? Until last weekend, treatment for COVID-19 was primarily experimental. In hundreds of clinical trials across the globe, researchers are testing new drugs, as well as those that scientists created for other purposes, to stem the death toll the world is facing.
On March 28, 2020, the FDA gave permission to doctors to use hydroxychloroquine sulfate and chloroquine phosphate products for the treatment of COVID-19 in adolescents and adults in situations where clinical trials were not an option.